Evidence map›Paper›PMID 19774471›Full record

ArticleCancer causes & control : CCC2010

Metabolic syndrome components and colorectal adenoma in the CLUE II cohort.

Konstantinos K Tsilidis, Frederick L Brancati, Michael N Pollak, Nader Rifai, Sandra L Clipp, Judith Hoffman-Bolton, Kathy J Helzlsouer, Elizabeth A Platz

Open access · greenAbstract read
In one paragraph

Article in Cancer causes & control : CCC, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Trial
  6. Article
  7. Article
  8. Advances in laboratory medicine · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Sessile serrated adenomas versus conventional adenomas. Different polyps in different populations?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Konstantinos K TsilidisDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Frederick L Brancati
Michael N Pollak
Nader Rifai
Sandra L Clipp
Judith Hoffman-Bolton
Kathy J Helzlsouer
Elizabeth A Platz
Johns Hopkins University · USBoston Children's Hospital · USJewish General Hospital · CA

Funding

CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESISU01CA086308 · NCI · JOHNS HOPKINS UNIVERSITY · PI HELZLSOUER, KATHY J · 2000 to 2004
$4.2M
GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORTU01AG018033 · NIA · JOHNS HOPKINS UNIVERSITY · PI HOFFMAN, SANDRA · 1999 to 2003
$2.8M
NCI NIH HHS CA86308NCI NIH HHS U01 CA086308NIA NIH HHS AG18033NIA NIH HHS U01 AG018033
6 · The paper itself

Abstract

backgroundMetabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case-control study.

methodsColorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline.

resultsNo statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95% CI, 1.70-37.67), albeit based on small numbers.

conclusionOur findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.

Indexed as

AdenomaAdultBiomarkersBody Mass IndexCase-Control StudiesColorectal NeoplasmsFemaleHumansMaleMarylandMetabolic SyndromeMiddle AgedRisk FactorsBiomarkers

Identifiers

PMID19774471
PMCPMC3010872
OpenAlexW1967489953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.